<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>08800087700181</udiDi>
    <basicUdiDi>88000877KRV3CD021DR</basicUdiDi>
    <tradeName>Droplex KRAS Mutation Test v3</tradeName>
    <deviceName>Droplex KRAS Mutation Test v3</deviceName>
    <manufacturerName>Gencurix, Inc.</manufacturerName>
    <manufacturerSrn>KR-MF-000034097</manufacturerSrn>
    <authorisedRepresentativeName>Medical Technology Promedt Consulting GmbH</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DE-AR-000000085</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060202</emdnCode>
    <emdnDescription>K-RAS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CD021</reference>
    <placedOnMarketCountry>France</placedOnMarketCountry>
    <lastUpdated>2026-07-01T02:32:48.793Z</lastUpdated>
  </row>
  <row>
    <udiDi>08720211482427</udiDi>
    <basicUdiDi>872021148ME032ZH</basicUdiDi>
    <tradeName>SALSA MLPA Probemix ME032 UPD7-UPD14</tradeName>
    <deviceName>SALSA MLPA Probemix ME032 UPD7-UPD14</deviceName>
    <manufacturerName>MRC Holland B.V.</manufacturerName>
    <manufacturerSrn>NL-MF-000000437</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ME032-025R</reference>
    <placedOnMarketCountry>Netherlands</placedOnMarketCountry>
    <lastUpdated>2026-07-01T00:44:26.289Z</lastUpdated>
  </row>
  <row>
    <udiDi>08720211480317</udiDi>
    <basicUdiDi>872021148P0175M</basicUdiDi>
    <tradeName>SALSA MLPA Probemix P017 MEN1</tradeName>
    <deviceName>SALSA MLPA Probemix P017 MEN1</deviceName>
    <manufacturerName>MRC Holland B.V.</manufacturerName>
    <manufacturerSrn>NL-MF-000000437</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>P017-025R</reference>
    <placedOnMarketCountry>Netherlands</placedOnMarketCountry>
    <lastUpdated>2026-07-01T00:42:51.439Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057289091290</udiDi>
    <basicUdiDi>8057289090301CRTX0533Z</basicUdiDi>
    <tradeName>EasyPGX ready JAK2</tradeName>
    <deviceName>EasyPGX ready JAK2</deviceName>
    <manufacturerName>DIATECH PHARMACOGENETICS SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000018670</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>RTX053</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:11:34.294Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057289091252</udiDi>
    <basicUdiDi>8057289090301CRTX0523X</basicUdiDi>
    <tradeName>EasyPGX ready MLH1</tradeName>
    <deviceName>EasyPGX ready MLH1</deviceName>
    <manufacturerName>DIATECH PHARMACOGENETICS SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000018670</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>RTX052</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:11:33.088Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057289091245</udiDi>
    <basicUdiDi>8057289090301CRTX0513V</basicUdiDi>
    <tradeName>EasyPGX ready ESR1</tradeName>
    <deviceName>EasyPGX ready ESR1</deviceName>
    <manufacturerName>DIATECH PHARMACOGENETICS SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000018670</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>RTX051</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:11:27.087Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057289091153</udiDi>
    <basicUdiDi>8057289090301CRTX04848</basicUdiDi>
    <tradeName>EasyPGX ready NPM1 Quant</tradeName>
    <deviceName>EasyPGX ready NPM1 Quant</deviceName>
    <manufacturerName>DIATECH PHARMACOGENETICS SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000018670</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>RTX048</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:11:24.684Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057289091146</udiDi>
    <basicUdiDi>8057289090301CRTX0494A</basicUdiDi>
    <tradeName>EasyPGX ready MGMT</tradeName>
    <deviceName>EasyPGX ready MGMT</deviceName>
    <manufacturerName>DIATECH PHARMACOGENETICS SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000018670</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>RTX049</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:11:23.483Z</lastUpdated>
  </row>
  <row>
    <udiDi>08057289091139</udiDi>
    <basicUdiDi>8057289090301CRTX04746</basicUdiDi>
    <tradeName>EasyPGX ready NPM1 Screening</tradeName>
    <deviceName>EasyPGX ready NPM1 Screening</deviceName>
    <manufacturerName>DIATECH PHARMACOGENETICS SRL</manufacturerName>
    <manufacturerSrn>IT-MF-000018670</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>RTX047</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:11:17.488Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954368</udiDi>
    <basicUdiDi>7649995954PMNRASQ6139</basicUdiDi>
    <tradeName>Oncobit PM NRASQ61R Control 10rxn</tradeName>
    <deviceName>Oncobit PM NRASQ61</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-04-03-2</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:36.135Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954351</udiDi>
    <basicUdiDi>7649995954PMNRASQ6139</basicUdiDi>
    <tradeName>Oncobit PM NRASQ61R PPM 40rxn</tradeName>
    <deviceName>Oncobit PM NRASQ61</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-04-03-1</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:34.920Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954344</udiDi>
    <basicUdiDi>7649995954PMNRASQ6139</basicUdiDi>
    <tradeName>Oncobit PM NRASQ61L Control 10rxn</tradeName>
    <deviceName>Oncobit PM NRASQ61</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-04-02-2</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:28.918Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954337</udiDi>
    <basicUdiDi>7649995954PMNRASQ6139</basicUdiDi>
    <tradeName>Oncobit PM NRASQ61L PPM 40rxn</tradeName>
    <deviceName>Oncobit PM NRASQ61</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-04-02-1</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:27.732Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954320</udiDi>
    <basicUdiDi>7649995954PMNRASQ6139</basicUdiDi>
    <tradeName>Oncobit PM NRASQ61K Control 10rxn</tradeName>
    <deviceName>Oncobit PM NRASQ61</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-04-01-2</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:26.513Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954313</udiDi>
    <basicUdiDi>7649995954PMNRASQ6139</basicUdiDi>
    <tradeName>Oncobit PM NRASQ61K PPM 40rxn</tradeName>
    <deviceName>Oncobit PM NRASQ61</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-04-01-1</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:25.330Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954306</udiDi>
    <basicUdiDi>7649995954PMGNAQQ209RC</basicUdiDi>
    <tradeName>Oncobit PM GNAQ209P Control 10rxn</tradeName>
    <deviceName>Oncobit PM GNAQQ209</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-03-02-2</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:19.328Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954290</udiDi>
    <basicUdiDi>7649995954PMGNAQQ209RC</basicUdiDi>
    <tradeName>Oncobit PM GNAQ209P PPM 40rxn</tradeName>
    <deviceName>Oncobit PM GNAQQ209</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-03-02-1</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:18.121Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954283</udiDi>
    <basicUdiDi>7649995954PMGNAQQ209RC</basicUdiDi>
    <tradeName>Oncobit PM GNAQ209L Control 10rxn</tradeName>
    <deviceName>Oncobit PM GNAQQ209</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-03-01-2</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:16.907Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954276</udiDi>
    <basicUdiDi>7649995954PMGNAQQ209RC</basicUdiDi>
    <tradeName>Oncobit PM GNAQ209L PPM 40rxn</tradeName>
    <deviceName>Oncobit PM GNAQQ209</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-03-01-1</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:15.711Z</lastUpdated>
  </row>
  <row>
    <udiDi>07649995954269</udiDi>
    <basicUdiDi>7649995954PMGNA11Q20935</basicUdiDi>
    <tradeName>Oncobit PM GNA11Q209L Control 10rxn</tradeName>
    <deviceName>Oncobit PM GNA11Q209</deviceName>
    <manufacturerName>Oncobit AG</manufacturerName>
    <manufacturerSrn>CH-MF-000037436</manufacturerSrn>
    <authorisedRepresentativeName>MedEnvoy Global BV</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>NL-AR-000024028</authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W01060299</emdnCode>
    <emdnDescription>TESTS FOR ACQUIRED GENETIC OR CHROMOSOMAL ALTERATIONS - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PM-1-02-01-2</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:15:09.698Z</lastUpdated>
  </row>
</eudamedExport>